½ÃÀ庸°í¼­
»óǰÄÚµå
1260754

¼¼°èÀÇ CSF(µÅÁö¿­º´) ¹é½Å ½ÃÀå ºÐ¼®(2023³â)

Global Classical Swine Fever Vaccines Market Research Report 2023

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: QYResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ CSF(µÅÁö¿­º´) ¹é½Å ½ÃÀå ±Ô¸ð´Â 2022³â¿¡ 1¾ï 5,470¸¸ ´Þ·¯°¡ µÇ¸ç, 2029³â¿¡´Â 2¾ï 1,100¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£ Áß(2023-2029³â)¿¡ 4.6%ÀÇ CAGR·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

ºÏ¹ÌÀÇ CSF(µÅÁö¿­º´) ¹é½Å ½ÃÀå ±Ô¸ð´Â 2023³â 1,229¸¸ ´Þ·¯¿¡¼­ 2029³â 1,486¸¸ ´Þ·¯¿¡ À̸£¸ç, ¿¹Ãø ±â°£ Áß(2023-2029³â) 3.22%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹Ãø µË´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ CSF(µÅÁö¿­º´) ¹é½Å ½ÃÀå ±Ô¸ð´Â 2023³â 1¾ï 400¸¸ ´Þ·¯¿¡¼­ 2029³â 1¾ï 4,070¸¸ ´Þ·¯¿¡ À̸£¸ç ¿¹Ãø ±â°£ Áß(2023-2029³â) 5.17% CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Àü¼¼°è CSF(µÅÁö¿­º´) ¹é½ÅÀÇ ÁÖ¿ä Á¦Á¶¾÷ü·Î´Â WINSUN, Boehringer Ingelheim, CAHIC, SPAH, Merck, Ceva, Harbin Veterinary Research Institute, Qilu Animal Health Products Factory µîÀÌ ÀÖ½À´Ï´Ù. 2022³â¿¡´Â ¼¼°è »óÀ§ º¥´õ 5°³»ç¿¡¼­ ¼öÀÍ ±âÁØÀ¸·Î ¾à 50.49%ÀÇ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå CSF(µÅÁö¿­º´) ¹é½Å: ½ÃÀå °³¿ä

  • Á¦Ç°ÀÇ Á¤ÀÇ
  • CSF(µÅÁö¿­º´) ¹é½Å : À¯·¡º°
    • ¼¼°èÀÇ CSF(µÅÁö¿­º´) ¹é½Å ½ÃÀå ±Ý¾× : À¯·¡º° ºñ±³(2023-2029³â)
    • Á¶Á÷ ¹è¾ç À¯·¡
    • ¼¼Æ÷ÁÖ À¯·¡
  • CSF(µÅÁö¿­º´) ¹é½Å : ÆÇ¸Å ä³Îº°
    • ¼¼°èÀÇ CSF(µÅÁö¿­º´) ¹é½Å ½ÃÀå ±Ý¾× : ÆÇ¸Å ä³Îº°(2023-2029³â)
    • Á¤ºÎ ÀÔÂû
    • ½ÃÀå ÆÇ¸Å
  • ¼¼°èÀÇ CSF(µÅÁö¿­º´) ¹é½Å ½ÃÀå ±Ô¸ð, ÃßÁ¤¡¤¿¹Ãø
    • ¼¼°èÀÇ CSF(µÅÁö¿­º´) ¹é½Å ¼öÀÍ(2018-2029³â)
    • ¼¼°èÀÇ CSF(µÅÁö¿­º´) ¹é½Å ÆÇ¸Å(2018-2029³â)
    • ¼¼°èÀÇ CSF(µÅÁö¿­º´) ¹é½Å Æò±Õ ½ÃÀå °¡°Ý(2018-2029³â)
  • ÀüÁ¦¡¤Á¦¾à Á¶°Ç

Á¦2Àå ½ÃÀå °æÀï : Á¦Á¶¾÷üº°

  • ¼¼°èÀÇ CSF(µÅÁö¿­º´) ¹é½Å ÆÇ¸ÅÀÇ ½ÃÀå Á¡À¯À² : Á¦Á¶¾÷üº°(2018-2023³â)
  • ¼¼°èÀÇ CSF(µÅÁö¿­º´) ¹é½Å ¼öÀÍÀÇ ½ÃÀå Á¡À¯À² : Á¦Á¶¾÷üº°(2019-2023³â)
  • ¼¼°èÀÇ CSF(µÅÁö¿­º´) ¹é½Å Æò±Õ °¡°Ý:Á¦Á¶¾÷üº°(2019-2023³â)
  • ¼¼°èÀÇ CSF(µÅÁö¿­º´) ¹é½Å ÁÖ¿ä ±â¾÷:¾÷°è ·©Å·(2021³â¡¤2022³â)
  • ¼¼°èÀÇ CSF(µÅÁö¿­º´) ¹é½Å ÁÖ¿ä Á¦Á¶¾÷ü : Á¦°ø ¿¡¸®¾î?º»»ç
  • ¼¼°èÀÇ CSF(µÅÁö¿­º´) ¹é½Å ÁÖ¿ä Á¦Á¶¾÷ü : Á¦Ç° Á¾·ù¿Í ¿ëµµ
  • ¼¼°èÀÇ CSF(µÅÁö¿­º´) ¹é½Å ÁÖ¿ä Á¦Á¶¾÷ü : ¼³¸³ ½Ã±â
  • ¼¼°è CSF(µÅÁö¿­º´) ¹é½Å ½ÃÀå : °æÀï »óȲ°ú µ¿Çâ

Á¦3Àå ¼¼°èÀÇ CSF(µÅÁö¿­º´) ¹é½Å ½ÃÀå ½Ã³ª¸®¿À:Áö¿ªº°

  • ¼¼°èÀÇ CSF(µÅÁö¿­º´) ¹é½Å ½ÃÀå ±Ô¸ð:Áö¿ªº°(2018³â¡¤2022³â¡¤2029³â)
  • ¼¼°èÀÇ CSF(µÅÁö¿­º´) ¹é½Å ÆÇ¸Å:Áö¿ªº°(2018-2029³â)
  • ¼¼°èÀÇ CSF(µÅÁö¿­º´) ¹é½Å ¼öÀÍ:Áö¿ªº°(2018-2029³â)
  • ºÏ¹Ì CSF(µÅÁö¿­º´) ¹é½Å ½ÃÀåÀÇ »ç½Ç°ú ¼öÄ¡ : ±¹°¡º°
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´ CSF(µÅÁö¿­º´) ¹é½Å ½ÃÀåÀÇ »ç½Ç°ú ¼öÄ¡ : ±¹°¡º°
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ·¯½Ã¾Æ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç CSF(µÅÁö¿­º´) ¹é½Å ½ÃÀåÀÇ »ç½Ç°ú ¼öÄ¡ : Áö¿ªº°
    • Áß±¹
    • ÀϺ»
    • Çѱ¹
    • Àεµ
    • È£ÁÖ
    • µ¿³²¾Æ½Ã¾Æ
  • ³²¹ÌÀÇ CSF(µÅÁö¿­º´) ¹é½Å ½ÃÀå »ç½Ç°ú ¼öÄ¡ : ±¹°¡º°
    • ºê¶óÁú
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ CSF(µÅÁö¿­º´) ¹é½Å ½ÃÀå »ç½Ç°ú ¼öÄ¡ : ±¹°¡
    • Áßµ¿
    • ¾ÆÇÁ¸®Ä«

Á¦4Àå ºÎ¹®: À¯·¡º°

  • ¼¼°èÀÇ CSF(µÅÁö¿­º´) ¹é½Å ÆÇ¸Å : À¯·¡º°(2018-2029³â)
  • ¼¼°èÀÇ CSF(µÅÁö¿­º´) ¹é½Å ¼öÀÍ : À¯·¡º°(2018-2029³â)
  • ¼¼°èÀÇ CSF(µÅÁö¿­º´) ¹é½Å °¡°Ý : À¯·¡º°(2018-2029³â)

Á¦5Àå ºÎ¹®: ÆÇ¸Å ä³Îº°

  • ¼¼°èÀÇ CSF(µÅÁö¿­º´) ¹é½Å ÆÇ¸Å : ÆÇ¸Å ä³Îº°(2018-2029³â)
  • ¼¼°èÀÇ CSF(µÅÁö¿­º´) ¹é½Å ¼öÀÍ : ÆÇ¸Å ä³Îº°(2018-2029³â)
  • ¼¼°èÀÇ CSF(µÅÁö¿­º´) ¹é½Å °¡°Ý : ÆÇ¸Å ä³Îº°(2018-2029³â)

Á¦6Àå ÁÖ¿ä ±â¾÷ °³¿ä

  • WINSUN
  • Boehringer Ingelheim
  • CAHIC
  • SPAH
  • Merck
  • Ceva
  • Harbin Veterinary Research Institute
  • Qilu Animal Health Products Factory
  • Ringpu Biology
  • DHN
  • CAVAC
  • Komipharm
  • Agrovet
  • Bioveta
  • Jinyu Bio-Technology
  • Institutul Pasteur
  • MVP
  • Tecon

Á¦7Àå »ê¾÷ üÀΰú ÆÇ¸Å ä³Î ºÐ¼®

  • CSF(µÅÁö¿­º´) ¹é½ÅÀÇ »ê¾÷ üÀÎ ºÐ¼®
  • CSF(µÅÁö¿­º´) ¹é½ÅÀÇ ÁÖ¿ä ¿øÀç·á
  • CSF(µÅÁö¿­º´) ¹é½ÅÀÇ Á¦Á¶ ¸ðµå¿Í ÇÁ·Î¼¼½º
  • CSF(µÅÁö¿­º´) ¹é½ÅÀÇ ÆÇ¸Å¿Í ¸¶ÄÉÆÃ
  • CSF(µÅÁö¿­º´) ¹é½Å °í°´

Á¦8Àå CSF(µÅÁö¿­º´) ¹é½ÅÀÇ ½ÃÀå ¿ªÇÐ

  • CSF(µÅÁö¿­º´) ¹é½Å ¾÷°èÀÇ µ¿Çâ
  • CSF(µÅÁö¿­º´) ¹é½Å ½ÃÀåÀÇ ÃËÁø¿äÀÎ
  • CSF(µÅÁö¿­º´) ¹é½Å ½ÃÀåÀÇ °úÁ¦
  • CSF(µÅÁö¿­º´) ¹é½Å ½ÃÀåÀÇ ¾ïÁ¦¿äÀÎ

Á¦9Àå Á¶»ç °á°ú¿Í °á·Ð

Á¦10Àå Á¶»ç ¹æ¹ý°ú µ¥ÀÌÅÍ ¼Ò½º

ksm 23.05.03

The global Classical Swine Fever Vaccines market was valued at US$ 154.7 million in 2022 and is anticipated to reach US$ 211 million by 2029, witnessing a CAGR of 4.6% during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.

North American market for Classical Swine Fever Vaccines is estimated to increase from $ 12.29 million in 2023 to reach $ 14.86 million by 2029, at a CAGR of 3.22% during the forecast period of 2023 through 2029.

Asia-Pacific market for Classical Swine Fever Vaccines is estimated to increase from $ 104 million in 2023 to reach $ 140.7 million by 2029, at a CAGR of 5.17% during the forecast period of 2023 through 2029.

The major global manufacturers of Classical Swine Fever Vaccines include: WINSUN, Boehringer Ingelheim, CAHIC, SPAH, Merck, Ceva, Harbin Veterinary Research Institute, and Qilu Animal Health Products Factory, etc. In 2022, the world's top five vendors accounted for approximately 50.49% of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Classical Swine Fever Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Classical Swine Fever Vaccines.

The Classical Swine Fever Vaccines market size, estimations, and forecasts are provided in terms of sales volume (M Doses) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Classical Swine Fever Vaccines market comprehensively. Regional market sizes, concerning products by Source, by Sales Channel, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Classical Swine Fever Vaccines manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Source, by Sales Channel, and by regions.

By Company

  • WINSUN
  • Boehringer Ingelheim
  • CAHIC
  • SPAH
  • Merck
  • Ceva
  • Harbin Veterinary Research Institute
  • Qilu Animal Health Products Factory
  • Ringpu Biology
  • DHN
  • CAVAC
  • Komipharm
  • Agrovet
  • Bioveta
  • Jinyu Bio-Technology
  • Institutul Pasteur
  • MVP
  • Tecon

Segment by Source

  • Tissue Culture Origin
  • Cell Line Origin

Segment by Sales Channel

  • Government Tender
  • Market Sales

Consumption by Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Russia
    • Rest of Europe
  • South America
    • Brazil
    • Rest of South America

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Classical Swine Fever Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Classical Swine Fever Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Source, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Sales Channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report.

Table of Contents

1 Classical Swine Fever Vaccines Market Overview

  • 1.1 Product Definition
  • 1.2 Classical Swine Fever Vaccines by Source
    • 1.2.1 Global Classical Swine Fever Vaccines Market Value Comparison by Source (2023-2029)
    • 1.2.2 Tissue Culture Origin
    • 1.2.3 Cell Line Origin
  • 1.3 Classical Swine Fever Vaccines by Sales Channel
    • 1.3.1 Global Classical Swine Fever Vaccines Market Value by Sales Channel (2023-2029)
    • 1.3.2 Government Tender
    • 1.3.3 Market Sales
  • 1.4 Global Classical Swine Fever Vaccines Market Size Estimates and Forecasts
    • 1.4.1 Global Classical Swine Fever Vaccines Revenue 2018-2029
    • 1.4.2 Global Classical Swine Fever Vaccines Sales 2018-2029
    • 1.4.3 Global Classical Swine Fever Vaccines Market Average Price (2018-2029)
  • 1.5 Assumptions and Limitations

2 Classical Swine Fever Vaccines Market Competition by Manufacturers

  • 2.1 Global Classical Swine Fever Vaccines Sales Market Share by Manufacturers (2018-2023)
  • 2.2 Global Classical Swine Fever Vaccines Revenue Market Share by Manufacturers (2019-2023)
  • 2.3 Global Classical Swine Fever Vaccines Average Price by Manufacturers (2019-2023)
  • 2.4 Global Key Players of Classical Swine Fever Vaccines, Industry Ranking, 2021 VS 2022
  • 2.5 Global Key Manufacturers of Classical Swine Fever Vaccines, Area Served & Headquarters
  • 2.6 Global Key Manufacturers of Classical Swine Fever Vaccines, Product Type & Application
  • 2.7 Founded Data of Global Key Classical Swine Fever Vaccines Manufacturers
  • 2.8 Global Classical Swine Fever Vaccines Market Competitive Situation and Trends
    • 2.8.1 Global Classical Swine Fever Vaccines Market Concentration Rate
    • 2.8.2 The Global 5 and 10 Largest Classical Swine Fever Vaccines Players Market Share by Revenue
    • 2.8.3 Global Classical Swine Fever Vaccines by Company Type (Tier 1, Tier 2, and Tier 3)

3 Global Classical Swine Fever Vaccines Market Scenario by Region

  • 3.1 Global Classical Swine Fever Vaccines Market Size by Region: 2018 Versus 2022 Versus 2029
  • 3.2 Global Classical Swine Fever Vaccines Sales by Region: 2018-2029
    • 3.2.1 Global Classical Swine Fever Vaccines Sales by Region: 2018-2023
    • 3.2.2 Global Classical Swine Fever Vaccines Sales by Region: 2024-2029
  • 3.3 Global Classical Swine Fever Vaccines Revenue by Region: 2018-2029
    • 3.3.1 Global Classical Swine Fever Vaccines Revenue by Region: 2018-2023
    • 3.3.2 Global Classical Swine Fever Vaccines Revenue by Region: 2024-2029
  • 3.4 North America Classical Swine Fever Vaccines Market Facts & Figures by Country
    • 3.4.1 North America Classical Swine Fever Vaccines Market Size by Country: 2018 VS 2022 VS 2029
    • 3.4.2 North America Classical Swine Fever Vaccines Sales by Country (2018-2029)
    • 3.4.3 North America Classical Swine Fever Vaccines Revenue by Country (2018-2029)
    • 3.4.4 U.S.
    • 3.4.5 Canada
    • 3.4.6 Mexico
  • 3.5 Europe Classical Swine Fever Vaccines Market Facts & Figures by Country
    • 3.5.1 Europe Classical Swine Fever Vaccines Market Size by Country: 2018 VS 2022 VS 2029
    • 3.5.2 Europe Classical Swine Fever Vaccines Sales by Country (2018-2029)
    • 3.5.3 Europe Classical Swine Fever Vaccines Revenue by Country (2018-2029)
    • 3.5.4 Germany
    • 3.5.5 France
    • 3.5.6 U.K.
    • 3.5.7 Italy
    • 3.5.8 Russia
  • 3.6 Asia Pacific Classical Swine Fever Vaccines Market Facts & Figures by Region
    • 3.6.1 Asia Pacific Classical Swine Fever Vaccines Market Size by Region: 2018 VS 2022 VS 2029
    • 3.6.2 Asia Pacific Classical Swine Fever Vaccines Sales by Region (2018-2029)
    • 3.6.3 Asia Pacific Classical Swine Fever Vaccines Revenue by Region (2018-2029)
    • 3.6.4 China
    • 3.6.5 Japan
    • 3.6.6 South Korea
    • 3.6.7 India
    • 3.6.8 Australia
    • 3.6.9 Southeast Asia
  • 3.7 South America Classical Swine Fever Vaccines Market Facts & Figures by Country
    • 3.7.1 South America Classical Swine Fever Vaccines Market Size by Country: 2018 VS 2022 VS 2029
    • 3.7.2 South America Classical Swine Fever Vaccines Sales by Country (2018-2029)
    • 3.7.3 South America Classical Swine Fever Vaccines Revenue by Country
    • 3.7.4 Brazil
  • 3.8 Middle East and Africa Classical Swine Fever Vaccines Market Facts & Figures by Country
    • 3.8.1 Middle East and Africa Classical Swine Fever Vaccines Market Size by Country: 2018 VS 2022 VS 2029
    • 3.8.2 Middle East and Africa Classical Swine Fever Vaccines Sales by Country (2018-2029)
    • 3.8.3 Middle East and Africa Classical Swine Fever Vaccines Revenue by Country
    • 3.8.4 Middle East
    • 3.8.5 Africa

4 Segment by Source

  • 4.1 Global Classical Swine Fever Vaccines Sales by Source (2018-2029)
    • 4.1.1 Global Classical Swine Fever Vaccines Sales by Source (2018-2023)
    • 4.1.2 Global Classical Swine Fever Vaccines Sales by Source (2024-2029)
    • 4.1.3 Global Classical Swine Fever Vaccines Sales Market Share by Source (2018-2029)
  • 4.2 Global Classical Swine Fever Vaccines Revenue by Source (2018-2029)
    • 4.2.1 Global Classical Swine Fever Vaccines Revenue by Source (2018-2023)
    • 4.2.2 Global Classical Swine Fever Vaccines Revenue by Source (2024-2029)
    • 4.2.3 Global Classical Swine Fever Vaccines Revenue Market Share by Source (2018-2029)
  • 4.3 Global Classical Swine Fever Vaccines Price by Source (2018-2029)

5 Segment by Sales Channel

  • 5.1 Global Classical Swine Fever Vaccines Sales by Sales Channel (2018-2029)
    • 5.1.1 Global Classical Swine Fever Vaccines Sales by Sales Channel (2018-2023)
    • 5.1.2 Global Classical Swine Fever Vaccines Sales by Sales Channel (2024-2029)
    • 5.1.3 Global Classical Swine Fever Vaccines Sales Market Share by Sales Channel (2018-2029)
  • 5.2 Global Classical Swine Fever Vaccines Revenue by Sales Channel (2018-2029)
    • 5.2.1 Global Classical Swine Fever Vaccines Revenue by Sales Channel (2018-2023)
    • 5.2.2 Global Classical Swine Fever Vaccines Revenue by Sales Channel (2024-2029)
    • 5.2.3 Global Classical Swine Fever Vaccines Revenue Market Share by Sales Channel (2018-2029)
  • 5.3 Global Classical Swine Fever Vaccines Price by Sales Channel (2018-2029)

6 Key Companies Profiled

  • 6.1 WINSUN
    • 6.1.1 WINSUN Company Information
    • 6.1.2 WINSUN Description and Business Overview
    • 6.1.3 WINSUN Classical Swine Fever Vaccines Sales, Revenue and Gross Margin (2019-2023)
    • 6.1.4 WINSUN Classical Swine Fever Vaccines Product Portfolio
  • 6.2 Boehringer Ingelheim
    • 6.2.1 Boehringer Ingelheim Company Information
    • 6.2.2 Boehringer Ingelheim Description and Business Overview
    • 6.2.3 Boehringer Ingelheim Classical Swine Fever Vaccines Sales, Revenue and Gross Margin (2019-2023)
    • 6.2.4 Boehringer Ingelheim Classical Swine Fever Vaccines Product Portfolio
  • 6.3 CAHIC
    • 6.3.1 CAHIC Company Information
    • 6.3.2 CAHIC Description and Business Overview
    • 6.3.3 CAHIC Classical Swine Fever Vaccines Sales, Revenue and Gross Margin (2019-2023)
    • 6.3.4 CAHIC Classical Swine Fever Vaccines Product Portfolio
  • 6.4 SPAH
    • 6.4.1 SPAH Company Information
    • 6.4.2 SPAH Description and Business Overview
    • 6.4.3 SPAH Classical Swine Fever Vaccines Sales, Revenue and Gross Margin (2019-2023)
    • 6.4.4 SPAH Classical Swine Fever Vaccines Product Portfolio
  • 6.5 Merck
    • 6.5.1 Merck Company Information
    • 6.5.2 Merck Description and Business Overview
    • 6.5.3 Merck Classical Swine Fever Vaccines Sales, Revenue and Gross Margin (2019-2023)
    • 6.5.4 Merck Classical Swine Fever Vaccines Product Portfolio
  • 6.6 Ceva
    • 6.6.1 Ceva Company Information
    • 6.6.2 Ceva Description and Business Overview
    • 6.6.3 Ceva Classical Swine Fever Vaccines Sales, Revenue and Gross Margin (2019-2023)
    • 6.6.4 Ceva Classical Swine Fever Vaccines Product Portfolio
  • 6.7 Harbin Veterinary Research Institute
    • 6.7.1 Harbin Veterinary Research Institute Company Information
    • 6.7.2 Harbin Veterinary Research Institute Description and Business Overview
    • 6.7.3 Harbin Veterinary Research Institute Classical Swine Fever Vaccines Sales, Revenue and Gross Margin (2019-2023)
    • 6.7.4 Harbin Veterinary Research Institute Classical Swine Fever Vaccines Product Portfolio
  • 6.8 Qilu Animal Health Products Factory
    • 6.8.1 Qilu Animal Health Products Factory Company Information
    • 6.8.2 Qilu Animal Health Products Factory Description and Business Overview
    • 6.8.3 Qilu Animal Health Products Factory Classical Swine Fever Vaccines Sales, Revenue and Gross Margin (2019-2023)
    • 6.8.4 Qilu Animal Health Products Factory Classical Swine Fever Vaccines Product Portfolio
  • 6.9 Ringpu Biology
    • 6.9.1 Ringpu Biology Company Information
    • 6.9.2 Ringpu Biology Description and Business Overview
    • 6.9.3 Ringpu Biology Classical Swine Fever Vaccines Sales, Revenue and Gross Margin (2019-2023)
    • 6.9.4 Ringpu Biology Classical Swine Fever Vaccines Product Portfolio
  • 6.10 DHN
    • 6.10.1 DHN Company Information
    • 6.10.2 DHN Description and Business Overview
    • 6.10.3 DHN Classical Swine Fever Vaccines Sales, Revenue and Gross Margin (2019-2023)
    • 6.10.4 DHN Classical Swine Fever Vaccines Product Portfolio
  • 6.11 CAVAC
    • 6.11.1 CAVAC Company Information
    • 6.11.2 CAVAC Description and Business Overview
    • 6.11.3 CAVAC Classical Swine Fever Vaccines Sales, Revenue and Gross Margin (2019-2023)
    • 6.11.4 CAVAC Classical Swine Fever Vaccines Product Portfolio
  • 6.12 Komipharm
    • 6.12.1 Komipharm Company Information
    • 6.12.2 Komipharm Description and Business Overview
    • 6.12.3 Komipharm Classical Swine Fever Vaccines Sales, Revenue and Gross Margin (2019-2023)
    • 6.12.4 Komipharm Classical Swine Fever Vaccines Product Portfolio
  • 6.13 Agrovet
    • 6.13.1 Agrovet Company Information
    • 6.13.2 Agrovet Description and Business Overview
    • 6.13.3 Agrovet Classical Swine Fever Vaccines Sales, Revenue and Gross Margin (2019-2023)
    • 6.13.4 Agrovet Classical Swine Fever Vaccines Product Portfolio
  • 6.14 Bioveta
    • 6.14.1 Bioveta Company Information
    • 6.14.2 Bioveta Description and Business Overview
    • 6.14.3 Bioveta Classical Swine Fever Vaccines Sales, Revenue and Gross Margin (2019-2023)
    • 6.14.4 Bioveta Classical Swine Fever Vaccines Product Portfolio
  • 6.15 Jinyu Bio-Technology
    • 6.15.1 Jinyu Bio-Technology Company Information
    • 6.15.2 Jinyu Bio-Technology Description and Business Overview
    • 6.15.3 Jinyu Bio-Technology Classical Swine Fever Vaccines Sales, Revenue and Gross Margin (2019-2023)
    • 6.15.4 Jinyu Bio-Technology Classical Swine Fever Vaccines Product Portfolio
  • 6.16 Institutul Pasteur
    • 6.16.1 Institutul Pasteur Company Information
    • 6.16.2 Institutul Pasteur Description and Business Overview
    • 6.16.3 Institutul Pasteur Classical Swine Fever Vaccines Sales, Revenue and Gross Margin (2019-2023)
    • 6.16.4 Institutul Pasteur Classical Swine Fever Vaccines Product Portfolio
  • 6.17 MVP
    • 6.17.1 MVP Company Information
    • 6.17.2 MVP Description and Business Overview
    • 6.17.3 MVP Classical Swine Fever Vaccines Sales, Revenue and Gross Margin (2019-2023)
    • 6.17.4 MVP Classical Swine Fever Vaccines Product Portfolio
  • 6.18 Tecon
    • 6.18.1 Tecon Company Information
    • 6.18.2 Tecon Description and Business Overview
    • 6.18.3 Tecon Classical Swine Fever Vaccines Sales, Revenue and Gross Margin (2019-2023)
    • 6.18.4 Tecon Classical Swine Fever Vaccines Product Portfolio

7 Industry Chain and Sales Channels Analysis

  • 7.1 Classical Swine Fever Vaccines Industry Chain Analysis
  • 7.2 Classical Swine Fever Vaccines Key Raw Materials
    • 7.2.1 Key Raw Materials
    • 7.2.2 Raw Materials Key Suppliers
  • 7.3 Classical Swine Fever Vaccines Production Mode & Process
  • 7.4 Classical Swine Fever Vaccines Sales and Marketing
    • 7.4.1 Classical Swine Fever Vaccines Sales Channels
    • 7.4.2 Classical Swine Fever Vaccines Distributors
  • 7.5 Classical Swine Fever Vaccines Customers

8 Classical Swine Fever Vaccines Market Dynamics

  • 8.1 Classical Swine Fever Vaccines Industry Trends
  • 8.2 Classical Swine Fever Vaccines Market Drivers
  • 8.3 Classical Swine Fever Vaccines Market Challenges
  • 8.4 Classical Swine Fever Vaccines Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

  • 10.1 Methodology/Research Approach
    • 10.1.1 Research Programs/Design
    • 10.1.2 Market Size Estimation
    • 10.1.3 Market Breakdown and Data Triangulation
  • 10.2 Data Source
    • 10.2.1 Secondary Sources
    • 10.2.2 Primary Sources
  • 10.3 Author List
  • 10.4 Disclaimer
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦